BELLUS Health Inc BLUSD

Primary Symbol: T.BLU

Healthcare Biotechnology

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

TSX:BLU - Post by User

BELLUS Health Inc > GSK offer at $14.75 cash USD

<< Previous

Bullboard Posts

Next >>

Comment by Possibleidiot01on Apr 18, 2023 12:05pm

151 Views

Post# 35400792

RE:RE:GSK offer at $14.75 cash USD

That's really a decision only you can make.
If it was my choice , I would tend to keep the shares and let it all unfold.It's a clean offer , by which I mean it's all cash and by a company that definitely has the money. and therefore the offer is not likely to disappear ( I don't like being given shares as part of a deal ).
On the other hand , if you have some other stock you want to buy ...... Bellus is not likely to go up a lot more.